Vaxxinity, Inc.

Equities

VAXX

US92244V1044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:59:25 09/05/2024 BST			5-day change	1st Jan Change
0.1 ^USD	-9.99%		-4.03%	-88.24%

05-08	Vaxxinity, Inc.(OTCPK:VAXX) dropped from NASDAQ Composite Index	CI
04-22	Sector Update: Health Care Stocks Advance Premarket Monday	MT

Vaxxinity, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022

March 26, 2023

Vaxxinity, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 20.46 million compared to USD 47.65 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.48 a year ago.

Latest news about Vaxxinity, Inc.

Vaxxinity, Inc.(OTCPK:VAXX) dropped from NASDAQ Composite Index	05-07	CI
Sector Update: Health Care Stocks Advance Premarket Monday	04-22	MT
Sector Update: Health Care	04-22	MT
Vaxxinity to Voluntarily Delist From Nasdaq; Shares Sink After Hours	04-19	MT
Vaxxinity, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
North American Morning Briefing : Tech in Focus on -2-	03-25	DJ
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson?s Disease at AD/PD? 2024	03-07	CI
Vaxxinity, Inc. Announces the Publication of Data from Multiple Non-Human Primate Studies	02-15	CI
Vaxxinity, Inc. to Present Data from UB-312 Program in Parkinson's Disease at International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders	02-13	CI
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida	01-30	CI
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida	01-18	CI
Vaxxinity, Inc. Announces Resignation of Katherine Eade from the Board of Directors	12-01	CI
Researchers return to Alzheimer's vaccines, buoyed by recent drug success	11-20	RE
Vaxxinity, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Vaxxinity, Inc. Announces Executive Changes	28/09/23	CI
Vaxxinity, Inc.(OTCPK:VAXX) added to S&P Global BMI Index	17/09/23	CI
Baird Starts Vaxxinity With Outperform Rating, Price Target is $7	08/09/23	MT
Vaxxinity, Inc. Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease	10/08/23	CI
Vaxxinity, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Vaxxinity, Inc. Announces Executive Changes	27/07/23	CI
Vaxxinity Says B-312 Phase 1 Trial Shows Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients; Shares Rise	17/07/23	MT
Vaxxinity, Inc. Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients	17/07/23	CI
Vaxxinity Reports 'Positive' Results in Early-Stage Parkinson's Disease Trial	22/06/23	MT
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease	22/06/23	CI
Vaxxinity, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI

Chart Vaxxinity, Inc.

Duration

Period

More charts

Company Profile

Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the potential to enable a new class of medicines. Its pipeline consists of five lead programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Its pipeline includes UB-311, UB-312, VXX-301, VXX-401 and UB-313. It also has developed an infectious disease product candidate, UB-612, as a heterologous booster against COVID-19. Its UB-311, which targets the primary pathological process of Alzheimerâs disease (AD) and UB-312, which targets the pathological process of Parkinsonâs disease (PD) and other so-called synucleinopathies.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

	1st Jan change	Capi.
VAXXINITY, INC.	-88.24%	13.94M
MODERNA, INC.	+23.37%	47.02B
LONZA GROUP AG	+49.84%	41.86B
IQVIA HOLDINGS INC.	-0.94%	41.76B
CELLTRION, INC.	-4.27%	28.8B
ICON PUBLIC LIMITED COMPANY	+11.29%	26.05B
ALNYLAM PHARMACEUTICALS, INC.	-20.92%	19.15B
BIO-TECHNE CORPORATION	+3.20%	12.55B
MEDPACE HOLDINGS, INC.	+30.23%	12.34B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.82B

Other Biotechnology & Medical Research

Vaxxinity, Inc.

Equities

VAXX

US92244V1044

Biotechnology & Medical Research

Vaxxinity, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022

Latest news about Vaxxinity, Inc.

Chart Vaxxinity, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research